Processa Pharma에 대한 매도 수량은 투자자에게 Processa Pharma의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Processa Pharma (NASDAQ:PCSA) 주식, 공매도 수량 보고

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Deutsche Bank analyst George Hill maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $349 to $250.

Price Target

Analyst Ratings

Deutsche Bank Maintains Hold on Humana, Lowers Price Target to $250

VNOM

Live On CNBC, Kevin Simpson Announces Bought Viper Energy

Live On CNBC, Kevin Simpson Announces Bought CME Group

<h3>Gainers</h3>
<ul>
<li>EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares increased by 50.5% to $5.92 during Thursday's regular session. The company's market cap stands at $628.3 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock increased by 25.79% to $0.63. The market value of their outstanding shares is at $206.4 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares rose 13.29% to $0.75. The company's market cap stands at $214.6 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock moved upwards by 12.76% to $0.17. </li>
<li>Junee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNE#NASDAQ">JUNE</a>) stock rose 11.62% to $4.8. The company's market cap stands at $62.2 million. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares increased by 10.86% to $2.04. The company's market cap stands at $16.6 million. As per the press release, H1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares decreased by 16.2% to $1.5 during Thursday's regular session. The company's market cap stands at $14.7 million. </li>
<li>Youdao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) stock decreased by 15.3% to $5.04. The market value of their outstanding shares is at $602.3 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) stock declined by 11.26% to $6.34. The market value of their outstanding shares is at $40.8 million. </li>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares fell 9.58% to $1.7. The market value of their outstanding shares is at $29.9 million. </li>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) stock declined by 9.03% to $2.42. The market value of their outstanding shares is at $269.0 million. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) stock fell 8.73% to $1.83. The market value of their outstanding shares is at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EVGO

JUNE

JWEL

LITB

LOBO

NWTN

TCTM

TRNR

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 33.5% to $1.66 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares rose 31.53% to $1.46. The company's market cap stands at $62.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 30.98% to $1.99. The company's market cap stands at $3.5 million. </li>
<li>OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) stock increased by 20.96% to $3.52. The company's market cap stands at $73.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.84% to $0.6. The market value of their outstanding shares is at $10.3 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.26% to $0.86. The company's market cap stands at $51.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 21.5% to $1.13 during Thursday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock declined by 17.13% to $6.34. The company's market cap stands at $257.6 million. The company's, Q1 earnings came out today. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 16.64% to $4.06. The company's market cap stands at $9.2 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 15.7% to $1.45. The market value of their outstanding shares is at $3.4 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares declined by 14.01% to $2.21. The market value of their outstanding shares is at $89.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.85% to $1.96. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

BYSI

GCTK

OSTX

RNAZ

SNGX

TNFA

TOVX

VRCA

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares increased by 20.2% to $0.14 during Thursday's regular session. The market value of their outstanding shares is at $1.2 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATIF#NASDAQ">ATIF</a>) stock rose 15.59% to $0.89. The company's market cap stands at $10.6 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares increased by 13.43% to $1.52. The market value of their outstanding shares is at $38.4 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock rose 13.21% to $1.39. The market value of their outstanding shares is at $62.5 million. </li>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares rose 13.13% to $0.37. The company's market cap stands at $60.4 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock moved upwards by 12.78% to $0.53. The market value of their outstanding shares is at $10.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gaucho Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINO#NASDAQ">VINO</a>) stock decreased by 15.2% to $4.31 during Thursday's regular session. The market value of their outstanding shares is at $3.8 million. </li>
<li>ShiftPixy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) stock fell 9.68% to $0.69. The market value of their outstanding shares is at $5.1 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) stock fell 9.6% to $1.58. The company's market cap stands at $5.5 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock declined by 9.57% to $0.35. The company's market cap stands at $11.3 million. </li>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) stock decreased by 9.44% to $12.19. The market value of their outstanding shares is at $292.5 million. </li>
<li>Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) shares declined by 9.09% to $79.03. The company's market cap stands at $2.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATIF

HTOO

MYNA

PEGY

PGHL

PITA

PIXY

SGLY

STEM

VINO

12 Industrials Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>AMTD Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) stock increased by 22.0% to $4.77 during Thursday's regular session. The market value of their outstanding shares is at $916.5 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares moved upwards by 14.09% to $0.35. The company's market cap stands at $2.6 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNHP#NASDAQ">SLNHP</a>) stock rose 13.47% to $5.42. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) stock increased by 13.43% to $7.04. The company's market cap stands at $76.8 million. </li>
<li>GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) shares rose 12.64% to $3.6. The market value of their outstanding shares is at $91.7 million. </li>
<li>Verb Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares rose 12.0% to $0.05. The company's market cap stands at $7.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock fell 18.6% to $0.28 during Thursday's regular session. The company's market cap stands at $22.9 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) stock declined by 12.89% to $0.67. The market value of their outstanding shares is at $133.0 million. </li>
<li>Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares fell 12.53% to $4.18. The company's market cap stands at $14.3 million. </li>
<li>OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) stock decreased by 10.45% to $2.42. The market value of their outstanding shares is at $94.2 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares declined by 9.96% to $1.81. The market value of their outstanding shares is at $110.1 million. </li>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) shares fell 9.16% to $5.06. The market value of their outstanding shares is at $77.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATGL

AUID

BNZI

GSIT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MLGO

OCFT

SLNHP

VERB

12 Information Technology Stocks Moving In Thursday's Intraday Session

Blue Owl Said In Talks To Buy IPI Partners For About $1B

WIIM

UGRO

Urban-gro shares are trading higher after the company announced it signed a $12 million US cannabis industry contract.

In the current market session, Applied Mat Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) stock price is at $200.81, after a 0.17% decrease. However, over the past month, the company's stock spiked by 11.41%, and in the past year, by 43.14%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1727973022_0.png" alt="Past Year Chart" />

<h3>Applied Mat P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Applied Mat has a lower P/E than the aggregate P/E of 79.44 of the Semiconductors &amp; Semiconductor Equipment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727973022_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

AMAT

Price Over Earnings Overview: Applied Mat

Management

TSLA

Tesla Chief Information Officer Nagesh Saldi Is Leaving Company

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Islamic Resistance In Iraq Says It Attacked Target In South Israel

Palantir Technologies Inc (NYSE: PLTR) shares climbed 3.6% on Thursday after reports from the previous day that co-founder and chairman Peter Thiel has completed selling the maximum number of shares allowed under his trading plan set in May,<a href="https://www.benzinga.com/news/24/10/41145602/palantir-stock-is-moving-higher-wednesday-whats-going-on"> according to Barron's.</a>
The company&#8217;s recent success brings to mind Jim Cramer's evolving stance on Palantir. He once dismissed it as not even a &#8220;real company.&#8221; Less than a month later, he completely&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/23/04/32017123/john-oliver-joins-inverse-jim-cramer-craze-says-youd-live-50-years-after-cramer-predicts-y">changed his mind</a>.
What Happened:&nbsp;Palantir&nbsp;announced an expansion of its&nbsp;<a href="https://www.benzinga.com/news/23/04/31676496/whats-going-on-with-palantir-technologies-stock-today">partnership</a>&nbsp;with&nbsp;Microsoft Corp&nbsp;(NASDAQ:&nbsp;<a href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) in early 2023. Following the announcement, Cramer said the AI-focused data software company was really just a &#8220;series of press releases&#8221; made up&nbsp;<a href="https://www.benzinga.com/news/23/04/31684804/jim-cramer-trashes-palantir-c3-ai-says-they-arent-even-real-companies">for the &#8220;memesters.&#8221;</a>
He complained about Palantir CEO&nbsp;Alex Karp&#8217;s&nbsp;use of foul language on conference calls and said the company would be a lot more legitimate if Karp would &#8220;stop dropping F-bombs.&#8221;
About a month later, Palantir <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32293202/palantir-just-beat-earnings-and-the-stock-is-ripping-but-4-analysts-are-mixed">reported strong quarterly results</a> and Cramer quickly changed his mind on the Karp-led company.
&#8220;I&#8217;ve been very critical of Alex Karp and not just because I thought it was totally unnecessary for him to curse on the conference call, but they had been losing money hand over fist,&#8221; Cramer said at the time on CNBC&#8217;s &#8220;Squawk On The Street.&#8221;
&#8220;They made money, $17 million, and they actually forecast GAAP positive, and what they did is pivot.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40937841/jim-cramer-this-utilities-stock-is-a-buy-calls-wells-fargo-a-winner">Jim Cramer: This Utilities Stock Is A Buy, Calls Wells Fargo A &#8216;Winner&#8217;</a>
Previously, Palantir didn&#8217;t care about making money and&nbsp;the company was all about &#8220;world domination,&#8221; Cramer said: &#8220;They did the pivot that we have all been hoping for. It was a clear pivot and I think the stock should be up.&#8221;
In a letter to shareholders, Karp said he&nbsp;expected Palantir&nbsp;<a href="https://www.benzinga.com/news/earnings/23/05/32286656/why-palantir-stock-is-ripping-higher-today">to&nbsp;remain profitable</a>&nbsp;in each quarter&nbsp;through the end of 2023. The stock was up more than 20% on the heels of the company&#8217;s bullish forecast.
Cramer noted that he plans to take a closer look at the company now that it&#8217;s actually making money. He also expressed interest in what Palantir is doing for Ukraine in the ongoing war with Russia before highlighting new&nbsp;<a href="https://www.benzinga.com/news/earnings/23/05/32273478/palantir-delivers-another-profitable-quarter-touts-new-ai-platform-shares-surge">AI technology</a>&nbsp;that allows Palantir to&nbsp;&#8220;control the battlefield&#8221;:
&#8220;Look out,&nbsp;Russia,&#8221; Cramer said.
On a conference call with investors and analysts, Palantir said Ukrainian forces have been unleashing&nbsp;the company&#8217;s AI products with incredible speed.
&#8220;The future has already arrived,&#8221; the&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32293202/palantir-just-beat-earnings-and-the-stock-is-ripping-but-4-analysts-are-mixed">company stated</a>.
PLTR Price Action: When Cramer turned positive on Palantir in early 2023, the stock was trading below $10. Palantir shares were up 3.6%, trading at $38.87 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/23/04/31703954/early-palantir-investor-claps-back-at-jim-cramer-for-ludicrous-comments-says-palantir-st">Early Palantir Investor Claps Back At Jim Cramer For &#8216;Ludicrous&#8217; Comments, Says Palantir Stock Will More Than &#8216;Triple&#8217;</a></li>
</ul>
Photo: Flickr/Shutterstock.&nbsp;
Some elements of this story were previously reported by Benzinga and it has been updated.

Tech

General

PLTR

Jim Cramer Once Told Palantir CEO To 'Stop Dropping F-Bombs,' Then He Realized The Future Had 'Already Arrived'

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has recalled <a href="https://www.benzinga.com/topic/cybertruck" target="_blank" rel="noreferrer noopener">certain 2024 Cybertruck models.</a>
The <a target="_blank" href="https://www.nhtsa.gov/search-safety-issues#recall" rel="noreferrer noopener">recall </a>of around 27,185 Cybertrucks is due to a delay in the rearview camera image when shifting into reverse, which causes these vehicles to not meet the Federal Motor Vehicle Safety Standard (FMVSS) number 111 regarding &#8220;Rear Visibility.&#8221;
To address the issue, Tesla has issued a free over-the-air (OTA) software update. Notification letters to owners are expected to be mailed out on November 25.
Earlier in June, the EV giant recalled over 11,000&nbsp;Cybertrucks&nbsp;over concerns that its sail applique may come loose or detach from the vehicle while it is moving and nearly 12,000 Cybertrucks over <a target="_blank" href="https://www.benzinga.com/news/24/06/39473764/tesla-recalls-more-than-11-000-cybertrucks-over-applique-detachment-risk-and-nearly-12-000-for-winds" rel="noreferrer noopener">concerns that their windshield wiper might stop working</a>.
Read Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/09/40985179/tesla-model-y-could-end-fords-long-reign-as-americas-top-selling-vehicle-will-2024-be-the-year" rel="noreferrer noopener">Tesla Model Y Could End Ford's Long Reign As America's Top-Selling Vehicle: Will 2024 Be The Year?</a>
In April, Tesla recalled&nbsp;3,878 Cybertruck vehicles over concerns of unintentional acceleration. The company had said in a filing with the U.S. auto safety regulator&nbsp;National Highway Traffic Safety Administration that the accelerator pedal pad on the affected vehicles may dislodge and become trapped by the interior trim above the pedal, <a target="_blank" href="https://www.benzinga.com/government/24/04/38331377/tesla-recalls-over-3-800-cybertrucks-citing-unintended-acceleration-risk" rel="noreferrer noopener">thereby causing it to accelerate without the driver intending to.</a>
Tesa commenced deliveries of its&nbsp;Cybertruck&nbsp;in Mexico last month, making it the first country outside the U.S. <a target="_blank" href="https://www.benzinga.com/news/24/09/41039631/tesla-begins-cybertruck-deliveries-in-mexico-before-canada-first-country-to-get-the-stainless-steel" rel="noreferrer noopener">where the stainless steel truck is delivered.</a>
Tesla reported third-quarter deliveries&nbsp;of 462,890 vehicles, up 6.4% year-over-year and <a target="_blank" href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year" rel="noreferrer noopener">up 4.3% quarter-over-quarter.</a>
The company reported third-quarter production of 469,796 vehicles, up 9.1% year-over-year and up 14.4% quarter-over-quarter.
Price Action: TSLA shares are trading lower by 2.31% to $243.26 at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41145803/tesla-q3-deliveries-step-in-the-right-direction-analyst-says-more-heavy-lifting-nee" target="_blank" rel="noreferrer noopener">Tesla Q3 Deliveries &#8216;Step In The Right Direction&#8217;: Analyst Says More &#8216;Heavy Lifting&#8217; Needed From Elon Musk To Turn Growth Story Around</a></li>
</ul>

Equities

Tesla Recalls 27,185 Cybertruck Vehicles Over Rearview Camera Delay

California's recent emergency rules severely <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">limiting hemp-derived products</a> are making waves across the cannabis industry. Gov. Gavin Newsom&#8216;s swift action has already begun to reshape the market, raising concerns about its broader impact on businesses and consumers.
The emergency rules aimed at limiting unregulated hemp products, particularly those containing THC, have been met with mixed reactions. While some believe it is a necessary step toward ensuring product safety, others are worried about the long-term consequences for businesses that rely on these products.
<h1 class="wp-block-heading">Impact on Public Safety and Market Stability</h1>
Bryan Gerber, CEO of Hara Supply and upcoming speaker at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>, weighed in on the situation, explaining that while the ban might be disruptive, it also addresses a critical issue. 
&#8220;Governor Newsom&#8217;s ban on hemp THC products in California will have a significant effect on the state&#8217;s market, given the category&#8217;s prevalence in a variety of legal adult-use and medical products,&#8221; Gerber said.
He highlighted the health risks associated with unregulated products, which he believes are not being adequately controlled. &#8220;As these products are not currently regulated properly, they undoubtedly pose potential health risks, and upholding the highest standards of public safety should be a non-negotiable for cannabis regulators and the industry at large.&#8221;
The immediacy of the ban has already sent shockwaves across California's supply chain, particularly as it exposes how unregulated products have infiltrated the legal market. However, Gerber is optimistic that the ban could lead to a safer marketplace. 
&#8220;Banning this category until legitimate regulations are implemented is better for the market,&#8221; he noted. Gerber believes that ensuring safe, tested hemp THC from vetted companies is what consumers deserve and will ultimately strengthen the legal market.
<h1 class="wp-block-heading">Overall Regulatory Implications</h1>
California's decision could also set the tone for future regulations in other states and at the federal level. 
&#8220;How California navigates this ban could inform future regulatory and business decisions across the country,&#8221; Gerber explained. Federal legislation, including the 2018 Farm Bill, may face increased scrutiny as regulators assess the impact of hemp-derived THC products.
The path forward remains uncertain as industry leaders and businesses adapt to these new regulations. While some may struggle under the weight of these restrictions, others are hopeful that a more regulated market will benefit consumers and create a safer environment for cannabis products across the U.S.
Photo: Benzinga edit with images by Bureau of Reclamation via Wikimedia Commons and Rob Warner on Unsplash

Cannabis

Government

Events

Exclusives

Interview

California's Hemp Restrictions Spark Industry Debate: 'Banning This Category Is Better For The Market,' Says Expert

Financial giants have made a conspicuous bullish move on Starbucks. Our analysis of options history for Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) revealed 11 unusual trades.
Delving into the details, we found 54% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $1,603,569, and 3 were calls, valued at $96,080.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $105.0 for Starbucks, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Starbucks options trades today is 4275.2 with a total volume of 5,239.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Starbucks's big money trades within a strike price range of $85.0 to $105.0 over the last 30 days.
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972432_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.15</td>
<td>$10.95</td>
<td>$11.0</td>
<td>$95.00</td>
<td>$1.1M</td>
<td>6.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.75</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$95.00</td>
<td>$210.5K</td>
<td>2.6K</td>
<td>468</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$98.00</td>
<td>$105.0K</td>
<td>565</td>
<td>1</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$1.98</td>
<td>$1.71</td>
<td>$1.8</td>
<td>$95.00</td>
<td>$44.9K</td>
<td>554</td>
<td>3</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.4</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$95.00</td>
<td>$40.5K</td>
<td>6.6K</td>
<td>102</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
Having examined the options trading patterns of Starbucks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Starbucks</h3>
<ul>
<li>With a trading volume of 1,666,427, the price of SBUX is down by -0.63%, reaching $95.89.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 28 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Starbucks</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $103.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $115. 
&#x2A; An analyst from Jefferies has revised its rating downward to Underperform, adjusting the price target to $76. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Buy, adjusting the price target to $110. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Starbucks, targeting a price of $110. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $105. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

SBUX

Starbucks Options Trading: A Deep Dive into Market Sentiment

Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $93,000, and 6 were calls, valued at $314,820.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $32.0 for Pfizer over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 7268.62 with a total volume of 11,974.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $28.0 to $32.0 over the last 30 days.
<h3>Pfizer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972427_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.45</td>
<td>$0.44</td>
<td>$0.45</td>
<td>$30.00</td>
<td>$112.5K</td>
<td>16.8K</td>
<td>3.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.0</td>
<td>$4.15</td>
<td>$5.0</td>
<td>$30.00</td>
<td>$60.0K</td>
<td>247</td>
<td>4</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$0.32</td>
<td>$0.3</td>
<td>$0.31</td>
<td>$30.00</td>
<td>$48.4K</td>
<td>1.6K</td>
<td>296</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.62</td>
<td>$2.61</td>
<td>$2.62</td>
<td>$32.00</td>
<td>$47.1K</td>
<td>256</td>
<td>180</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.49</td>
<td>$28.50</td>
<td>$47.1K</td>
<td>656</td>
<td>6.9K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Pfizer</h3>
<ul>
<li>With a trading volume of 10,723,798, the price of PFE is down by -0.93%, reaching $28.34.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 26 days from now.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $45.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Pfizer's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in X usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for United States Steel. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 52% bearish. Among these notable options, 13 are puts, totaling $1,496,460, and 4 are calls, amounting to $133,520.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $52.5 for United States Steel during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in United States Steel's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to United States Steel's substantial trades, within a strike price spectrum from $25.0 to $52.5 over the preceding 30 days.
<h3>United States Steel Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727972422_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">802</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">602</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.2</td>
<td>$9.0</td>
<td>$9.2</td>
<td>$40.00</td>
<td>$183.9K</td>
<td>5.6K</td>
<td style="text-align: right;">402</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.75</td>
<td>$15.6</td>
<td>$15.9</td>
<td>$50.00</td>
<td>$157.4K</td>
<td>7.3K</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.0</td>
<td>$15.6</td>
<td>$16.0</td>
<td>$50.00</td>
<td>$156.8K</td>
<td>7.3K</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About United States Steel</h3>
United States Steel Corp operates primarily in the United States but also has a steelmaking capacity in Slovakia. The company's operating segments include North American Flat-Rolled (Flat-Rolled), Mini Mill, U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment includes U. S. Steel's integrated steel plants and equity investees in North America involved in the production of slabs, strip mill plates, sheets, and tin mill products, as well as all iron ore and coke production facilities in the United States. It primarily serves North American customers in the service center, conversion, transportation, construction, container, and appliance, and electrical markets.
<h3>Present Market Standing of United States Steel</h3>
<ul>
<li>With a volume of 768,153, the price of X is up 0.9% at $34.91. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>Professional Analyst Ratings for United States Steel</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $40.52333333333333.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on United States Steel with a target price of $41. 
&#x2A; Showing optimism, an analyst from GLJ Research upgrades its rating to Buy with a revised price target of $38. 
&#x2A; Showing optimism, an analyst from JP Morgan upgrades its rating to Overweight with a revised price target of $42. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for United States Steel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On United States Steel

AMZN

NFLX

PARA

Shares of streaming companies are trading lower after Amazon announced they will ramp up their Prime Video advertising spend.

In 1989, a couple from Long Island took a chance on an unclaimed storage unit for just $100, as reported by a CNBC article. They didn't expect to find a piece of movie history tucked away under some old blankets – a 1976 Lotus Esprit, used in the James Bond film The Spy Who Loved Me.
The couple, who had no clue what they stumbled upon, initially planned to fix the car's roof and do some minor work. But while hauling it home, truckers on the road started radioing them, letting them know they had something much more valuable – a James Bond car. After hearing this, the husband rented the movie and realized they were sitting on a treasure.&nbsp;
Don't Miss:
<ul>
<li>Unlock a $400 billion opportunity by investing in the future of EV infrastructure on<a href="https://www.benzinga.com/money/dunamis-1"> this startup already valued at $50 million with just $500</a>.</li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Ironically, the couple had reportedly never even seen a Bond film.&nbsp;
Years later, after some cosmetic touch-ups, they auctioned the car in 2013. That's when Elon Musk entered the picture, paying nearly $1 million for the Lotus – $997,000. Musk, who grew up watching the Bond movie, said, "It was amazing as a little kid to watch James Bond drive the Lotus Esprit off a pier and have it transform into a submarine."
In a statement to auto blog Jalopnik, Musk said, "I was disappointed to learn that it can&#8217;t transform. What I&#8217;m going to do is upgrade it with a Tesla electric powertrain and try to make it transform for real."
Interestingly, the car, nicknamed "Wet Nellie," was originally converted into a functional submarine for the movie, costing over $100,000. While it couldn't drive on land, it was fully capable of underwater action with propellers and ballast tanks. Instead of wheels, it had "articulated fins.&#8221;&nbsp;
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Musk's fascination with the Lotus Esprit didn't end at its purchase. He stated that the car significantly shaped the futuristic design of Tesla's Cybertruck, unveiled in 2019.&nbsp;
Musk <a href="https://x.com/elonmusk/status/1197638937109336066">posted on X</a> that the Cybertruck's sharp, angular design was "influenced partly" by the iconic Bond car, writing: "Cybertruck design influenced partly by The Spy Who Loved Me." He attached a YouTube clip of the movie.&nbsp;
Musk's desire to combine cutting-edge electric vehicle technology with a design inspired by his childhood memories of James Bond highlights the seamless blend of nostalgia and innovation at the heart of Tesla's boldest creations.
Read Next:
<ul>
<li>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Elon Musk Paid $1 Million For A 1976 Car That Inspired Cybertruck's Design – Seller Originally Bought It For Just $100 In A Storage Unit Sale

Processa Pharmaceuticals appoints CFO

Processa Pharmaceuticals (PCSA) has provided an update. Processa Pharmaceuticals, Inc. has appointed seasoned industry expert Russell Skibsted as t...

Processa Pharmaceuticals Welcomes New CFO Russell Skibsted

FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is rising higher on Tuesday after the company <a href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-fda-clearance-120000203.html">posted an update</a> from the Food and Drug Administration (FDA).



The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company&rsquo;s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.



With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.



David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.




&ldquo;We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.&rdquo;




<h2>PCSA Stock Movement Today</h2>



With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company&rsquo;s daily average trading volume of about 90,000 shares.



PCSA stock is up 29.4% as of Tuesday morning.



Investors seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Delta&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dal-stock-quote/">DAL</a>) and SoFi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>



<li><a href="https://investorplace.com/2024/07/dal-stock-delta-wants-crowdstrike-to-pay-up-for-flight-delays-caused-by-outage/">DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</a></li>



<li><a href="https://investorplace.com/2024/07/sofi-stock-sofi-just-raised-its-profit-guidance-again-whats-going-on/">SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What&rsquo;s Going On?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is still rallying higher as a bankruptcy filing has introduced an immense amount of volatility to the online education platform company&rsquo;s shares.



Today&rsquo;s movement has TWOU stock rallying 15.5% as of Tuesday morning. That comes with more than 31 million shares changing hands. For the record, its daily average trading volume is about 2.5 million shares.



The rally today <a href="https://investorplace.com/2024/07/2u-twou-stock-pops-more-than-100-despite-bankruptcy-filing/">follows a surge yesterday</a> that saw the stock jump as more than 100% higher during normal trading hours. It is worth noting that these rallies come after the stock suffered a roughly 60% drop when news of its bankruptcy broke.



<h2>What&rsquo;s Next for 2U Stock?</h2>



2U is using this bankruptcy to <a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">restructure its debt</a> via deals with lenders. This has the company continuing operations throughout the process. It expects to exit bankruptcy by the end of September.



It&rsquo;s also unclear how this bankruptcy filing will affect TWOU stock. While the company is only using it for restructuring, it could cause problems for its listing on the Nasdaq Exchange.



Also, all of this volatility makes TWOU stock a bit of a risky investment. Traders will want to keep that in mind before taking a stake in the company.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market stories that traders need to know about on Tuesday! That includes warnings of a potential market crash, why Processa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is up today and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

2U (TWOU) Stock Continues to Surge in Bankruptcy Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) just reported results for the second quarter of 2024.<ul><li>Processa Pharma reported earnings per share of -$1.01. This was below the analyst estimate for EPS of -98 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pcsa-stock-earnings-processa-pharma-for-q2-of-2024/">PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), H...

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)

Processa Pharmaceuticals reports GAAP EPS of -$1.01

Processa stock rallies 35% post-market on Phase 2 study update

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals (PCSA – Research Report), retaining the price target o...

Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap

PSNL

SOFI

TWOU

Press Releases

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Comments

Processa Pharma

매도 수량

Processa Pharma (NASDAQ:PCSA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌